NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response.

CONCLUSIONS: The expression level of ERBB2, ESR1, and few other genomic markers was highly predictive of pCR after trastuzumab-containing regimens. These findings need to be validated and calibrated in future studies.
PMID: 32371537 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - May 4, 2020 Category: Cancer & Oncology Authors: Swain SM, Tang G, Brauer HA, Goerlitz DS, Lucas PC, Robidoux A, Harris BT, Bandos H, Ren Y, Geyer CE, Rastogi P, Mamounas EP, Wolmark N Tags: Clin Cancer Res Source Type: research